Angiopoietin-Like 3: From Discovery to Therapeutic Gene Editing

Area of Science:

• Cardiovascular Science
• Lipid Metabolism
• Molecular Biology

Background:

• Hyperlipidemia is a primary driver of atherosclerosis and coronary heart disease (CHD).
• Angiopoietin-like 3 (ANGPTL3) plays a crucial role in regulating low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides.
• Genetic studies show naturally occurring ANGPTL3 loss-of-function mutations are associated with reduced CHD risk.

Purpose of the Study:

• To review the discovery and function of ANGPTL3 in lipoprotein metabolism.
• To examine the genetic evidence linking ANGPTL3 deficiency to lower coronary heart disease risk.
• To discuss current therapeutic strategies targeting ANGPTL3 for cardiovascular disease prevention.

Main Methods:

• Literature review of ANGPTL3 discovery and function.
• Analysis of genetic association studies on ANGPTL3 loss-of-function mutations and CHD.
• Overview of ongoing therapeutic developments targeting ANGPTL3.

Main Results:

• ANGPTL3 is a key regulator of major lipid profiles.
• Loss-of-function mutations in ANGPTL3 are genetically associated with protection against coronary heart disease.
• ANGPTL3 deficiency leads to favorable lipid profiles and reduced cardiovascular risk.

Conclusions:

• ANGPTL3 is a validated molecular target for managing dyslipidemia and reducing cardiovascular risk.
• Therapeutic strategies including monoclonal antibodies, antisense oligonucleotides, and gene editing are being developed to target ANGPTL3.
• Targeting ANGPTL3 holds significant promise for the prevention and treatment of atherosclerosis and coronary heart disease.